Literature DB >> 23026200

Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice.

Karelle Leroy1, Kunie Ando, Vincent Laporte, Robert Dedecker, Valérie Suain, Michèle Authelet, Céline Héraud, Nathalie Pierrot, Zehra Yilmaz, Jean-Noël Octave, Jean-Pierre Brion.   

Abstract

Lack of tau expression has been reported to protect against excitotoxicity and to prevent memory deficits in mice expressing mutant amyloid precursor protein (APP) identified in familial Alzheimer disease. In APP mice, mutant presenilin 1 (PS1) enhances generation of Aβ42 and inhibits cell survival pathways. It is unknown whether the deficient phenotype induced by concomitant expression of mutant PS1 is rescued by absence of tau. In this study, we have analyzed the effect of tau deletion in mice expressing mutant APP and PS1. Although APP/PS1/tau(+/+) mice had a reduced survival, developed spatial memory deficits at 6 months and motor impairments at 12 months, these deficits were rescued in APP/PS1/tau(-/-) mice. Neuronal loss and synaptic loss in APP/PS1/tau(+/+) mice were rescued in the APP/PS1/tau(-/-) mice. The amyloid plaque burden was decreased by roughly 50% in the cortex and the spinal cord of the APP/PS1/tau(-/-) mice. The levels of soluble and insoluble Aβ40 and Aβ42, and the Aβ42/Aβ40 ratio were reduced in APP/PS1/tau(-/-) mice. Levels of phosphorylated APP, of β-C-terminal fragments (CTFs), and of β-secretase 1 (BACE1) were also reduced, suggesting that β-secretase cleavage of APP was reduced in APP/PS1/tau(-/-) mice. Our results indicate that tau deletion had a protective effect against amyloid induced toxicity even in the presence of mutant PS1 and reduced the production of Aβ.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026200     DOI: 10.1016/j.ajpath.2012.08.012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.

Authors:  Sarah L DeVos; Bianca T Corjuc; Caitlin Commins; Simon Dujardin; Riley N Bannon; Diana Corjuc; Benjamin D Moore; Rachel E Bennett; Mehdi Jorfi; Jose A Gonzales; Patrick M Dooley; Allyson D Roe; Rose Pitstick; Daniel Irimia; Matthew P Frosch; George A Carlson; Bradley T Hyman
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 2.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

3.  Seizure resistance without parkinsonism in aged mice after tau reduction.

Authors:  Zhiyong Li; Alicia M Hall; Mark Kelinske; Erik D Roberson
Journal:  Neurobiol Aging       Date:  2014-05-09       Impact factor: 4.673

4.  Importance of tau in cognitive decline as revealed by developmental exposure to lead.

Authors:  K Wright; S W Bihaqi; A Lahouel; A Masoud; F Mushtaq; A Leso; A Eid; N H Zawia
Journal:  Toxicol Lett       Date:  2017-12-05       Impact factor: 4.372

Review 5.  Emerging Diagnostic and Therapeutic Strategies for Tauopathies.

Authors:  David Coughlin; David J Irwin
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 6.  D-ribose and pathogenesis of Alzheimer's disease.

Authors:  Mehjbeen Javed; Md Irshad Ahmad; Hina Javed; Sufia Naseem
Journal:  Mol Biol Rep       Date:  2020-01-13       Impact factor: 2.316

7.  Antisense reduction of tau in adult mice protects against seizures.

Authors:  Sarah L DeVos; Dustin K Goncharoff; Guo Chen; Carey S Kebodeaux; Kaoru Yamada; Floy R Stewart; Dorothy R Schuler; Susan E Maloney; David F Wozniak; Frank Rigo; C Frank Bennett; John R Cirrito; David M Holtzman; Timothy M Miller
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

Review 8.  Antisense oligonucleotides: treating neurodegeneration at the level of RNA.

Authors:  Sarah L DeVos; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 9.  Connecting the dots between tau dysfunction and neurodegeneration.

Authors:  Bess Frost; Jürgen Götz; Mel B Feany
Journal:  Trends Cell Biol       Date:  2014-08-26       Impact factor: 20.808

Review 10.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.